Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Inflammatory Response

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Inflammation

Inflammation

Acute Inflammation III: Local and Systemic Effects

Acute Inflammation III: Local and Systemic Effects

Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...

Acute Inflammation I: Inflammatory Response

Acute Inflammation I: Inflammatory Response

Acute inflammation is a rapid, short-lived physiological response to tissue injury or infection, designed to eliminate harmful agents and initiate repair. This tightly regulated process typically lasts from minutes to several days and is triggered by factors such as microbial invasion, physical trauma, or chemical injury.Recognition and Mediator ReleaseThe inflammatory response begins when resident immune cells—such as mast cells, macrophages, and dendritic cells—detect damage-associated...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The JAK1/3 inhibitor tofacitinib suppresses T cell homing and activation in chronic intestinal inflammation.

Journal of Crohn's & colitis·2020

Same author

Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis.

Journal of molecular medicine (Berlin, Germany)·2020

Same author

Functional Molecular Network Analysis Enables Prediction of Response to Vedolizumab Therapy in Anti-TNF Refractory IBD Patients.

Crohn's & colitis 360·2020

Same author

Topical application of Chlorin e6-PVP (Ce6-PVP) for improved endoscopic detection of neoplastic lesions in a murine colitis-associated cancer model.

Scientific reports·2020

Same author

Vascular occlusion by neutrophil extracellular traps in COVID-19.

EBioMedicine·2020

Same author

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion.

Nature communications·2020

Search research articles

Related Experiment Video

Updated: Jun 15, 2026

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Published on: January 26, 2016

Inflammation, peptides and biological therapy.

Raja Atreya¹, Markus F Neurath

¹Medical Clinic 1, University of Erlangen, Erlangen, Germany. raja.atreya@uk-erlangen.de

Digestive Diseases (Basel, Switzerland)

|March 6, 2010

Summary

Inflammatory bowel diseases involve chronic gut inflammation. New therapies target cytokine pathways and T cell resistance to apoptosis, offering hope for improved treatments.

Area of Science:

Gastroenterology
Immunology
Molecular Biology

Background:

Inflammatory bowel diseases (IBD) are chronic, relapsing gastrointestinal inflammations of unknown etiology.
Cytokine-mediated signaling pathways are critical in IBD pathogenesis.
These pathways enhance intestinal T cell resistance to apoptosis, a key factor in disease development.

Purpose of the Study:

To elucidate the role of cytokine-mediated pathways in IBD pathogenesis.
To explore the impact of these pathways on T cell apoptosis resistance.
To inform the development of novel therapeutic strategies for IBD.

Main Methods:

Analysis of cytokine-mediated signaling pathways in the gastrointestinal tract.
Investigation of T cell apoptosis resistance mechanisms in IBD.

More Related Videos

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

Published on: February 27, 2019

Related Experiment Videos

Last Updated: Jun 15, 2026

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Published on: January 26, 2016

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

Published on: February 27, 2019

Evaluation of existing and emerging biological therapies.

Main Results:

Identification of critical cytokine pathways driving intestinal inflammation in IBD.
Demonstration that these pathways increase T cell resistance to apoptosis.
Validation of anti-cytokine therapies in restoring mucosal T cell homeostasis.

Conclusions:

Understanding cytokine pathways and T cell apoptosis is crucial for IBD pathogenesis.
Targeting these pathways offers a rational basis for developing new IBD therapies.
Biological therapies, like anti-TNF and anti-IL-6R antibodies, show promise for effective and safer IBD treatment.